ES2094558T3 - Particulas para formacion de imagenes de resonancia magnetica nuclear (nmr) y metodo de fabricacion. - Google Patents

Particulas para formacion de imagenes de resonancia magnetica nuclear (nmr) y metodo de fabricacion.

Info

Publication number
ES2094558T3
ES2094558T3 ES93917714T ES93917714T ES2094558T3 ES 2094558 T3 ES2094558 T3 ES 2094558T3 ES 93917714 T ES93917714 T ES 93917714T ES 93917714 T ES93917714 T ES 93917714T ES 2094558 T3 ES2094558 T3 ES 2094558T3
Authority
ES
Spain
Prior art keywords
particles
coating
glycerophospholipid
micellar
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93917714T
Other languages
English (en)
Inventor
Herve Tournier
Roland Hyacinthe
Michel Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bracco International BV
Original Assignee
Bracco International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco International BV filed Critical Bracco International BV
Application granted granted Critical
Publication of ES2094558T3 publication Critical patent/ES2094558T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/832—Nanostructure having specified property, e.g. lattice-constant, thermal expansion coefficient
    • Y10S977/838—Magnetic property of nanomaterial
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/932—Specified use of nanostructure for electronic or optoelectronic application
    • Y10S977/953—Detector using nanostructure
    • Y10S977/96—Of magnetic property
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2991—Coated
    • Y10T428/2998—Coated including synthetic resin or polymer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Soft Magnetic Materials (AREA)
  • Oxygen, Ozone, And Oxides In General (AREA)
  • Hard Magnetic Materials (AREA)

Abstract

SE DESCRIBEN UNAS PARTICULAS DE MAGNETITA ADECUADAS PARA SU INYECCION EN LA CORRIENTE SANGUINEA DE PACIENTES QUE TIENEN UNA GRAN RESISTENCIA CONTRA LA AGLOMERACION Y ENTRADA MEDIANTE EL RES DEL HIGADO Y BAZO. LAS PARTICULAS CONSTAN ESENCIALMENTE DE UN NUCLEO DE OXIDO FERRICO Y UN REVESTIMIENTO TRIDIMENSIONAL QUE LO RODEA COMPUESTO DE UN SURFACTANTE GLICEROFOSFOLIPIDO O ESTER ALQUENIL, O UN ALQUILO MONOACIDO FOSFORICO. EL NUCLEO Y EL MONOESTER O UN GLICEROFOSFOLIPIDO MICELAR FORMAN UNA ESTRUCTURA TIPO --TANTE NO IONICO PARA PRODUCIR UN REVESTIMIENTO TRIDIMENSIONAL PROTECTOR QUE CEDE PARTICULAS CASI INDETECTABLES MEDIANTE LAS MACROFASES. LAS PARTICULAS PREPARADAS DE ACUERDO CON LA INVENCION SE MANTIENEN EN LA CIRCULACION DE LA SANGRE DURANTE LARGOS PERIODOS Y REPRESENTAN EXCELENTES AGENTES MAS DURADEROS DE COAGULACION SANGUINEA. LOS COMPONENTES PRINCIPALES DEL REVESTIMIENTO SON (A) ESPECIES ORGANICO-MINERALES POLIBASICAS TALES COMO UN ACIDO GLICERO FOSFATIDICO EN FORMA MICELAR Y (B) UN COPOLIMERO BLOQUE QUE TIENE SUCESIVOS SEGMENTOS HIDROFOBICOS E HIDROFILICOS.
ES93917714T 1992-08-13 1993-07-30 Particulas para formacion de imagenes de resonancia magnetica nuclear (nmr) y metodo de fabricacion. Expired - Lifetime ES2094558T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92810618 1992-08-13
EP93810380 1993-05-25

Publications (1)

Publication Number Publication Date
ES2094558T3 true ES2094558T3 (es) 1997-01-16

Family

ID=26132520

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93917714T Expired - Lifetime ES2094558T3 (es) 1992-08-13 1993-07-30 Particulas para formacion de imagenes de resonancia magnetica nuclear (nmr) y metodo de fabricacion.

Country Status (20)

Country Link
US (3) US5464696A (es)
EP (1) EP0607401B1 (es)
JP (1) JP2968588B2 (es)
KR (1) KR100307773B1 (es)
CN (1) CN1076205C (es)
AT (1) ATE144714T1 (es)
AU (1) AU660108B2 (es)
CA (1) CA2119654C (es)
DE (1) DE69305730T2 (es)
DK (1) DK0607401T3 (es)
ES (1) ES2094558T3 (es)
FI (1) FI941677A0 (es)
GR (1) GR3022288T3 (es)
HU (1) HU221805B1 (es)
IL (1) IL106493A (es)
IS (1) IS1648B (es)
MX (1) MX9304924A (es)
NO (1) NO307244B1 (es)
NZ (1) NZ254791A (es)
WO (1) WO1994004197A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US5520904A (en) * 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
TW319763B (es) * 1995-02-01 1997-11-11 Epix Medical Inc
DE19508772C2 (de) * 1995-03-01 1998-01-29 Schering Ag Verfahren und Verbindungen zur Detektion von Analyten mittels Remanenzmessung und deren Verwendung
US8071737B2 (en) * 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5833948A (en) * 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
DE19529921C2 (de) * 1995-08-01 1997-09-25 Schering Ag Verwendung von MRT-Kontrastmitteln zur Ventilations-Bildgebung der Lunge
ATE243230T1 (de) * 1995-11-01 2003-07-15 Bracco Research Sa Gelierte magnetisch markierte molekularsysteme als nmr-bilderzeugungsmittel
ATE291439T1 (de) 1996-01-10 2005-04-15 Amersham Health As Kontrastmittel
GB9600427D0 (en) * 1996-01-10 1996-03-13 Nycomed Imaging As Contrast media
AU7104598A (en) 1997-04-09 1998-10-30 Philipp Lang New technique to monitor drug delivery noninvasively (in vivo)
US6337215B1 (en) * 1997-12-01 2002-01-08 International Business Machines Corporation Magnetic particles having two antiparallel ferromagnetic layers and attached affinity recognition molecules
US6278893B1 (en) * 1998-01-05 2001-08-21 Nycomed Imaging As Method of magnetic resonance imaging of a sample with ex vivo polarization of an MR imaging agent
WO2000019227A1 (en) * 1998-09-28 2000-04-06 Nycomed Imaging As Method of magnetic resonance imaging
US6283448B1 (en) * 2000-04-19 2001-09-04 Daniel Webster Denton Offset butterfly valve
EP2286843A3 (en) 2000-06-02 2011-08-03 Bracco Suisse SA Compounds for targeting endothelial cells
US20050059031A1 (en) * 2000-10-06 2005-03-17 Quantum Dot Corporation Method for enhancing transport of semiconductor nanocrystals across biological membranes
DE60137953D1 (de) * 2000-10-06 2009-04-23 Life Technologies Corp Zellen mit spektraler signatur sowie verfahren zu ihrer herstellung und nutzung
US20090060992A1 (en) * 2002-05-08 2009-03-05 University Of Central Florida Research Foundation, Inc., Preparation of magneto-vesicles with DOPE/DDAB layers
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
KR101076053B1 (ko) 2003-02-04 2011-10-21 브라코 인터내셔날 비.브이. 초음파 조영제 및 그것의 제조방법
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
CA2547024C (en) * 2003-12-22 2013-12-17 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
JP2007515471A (ja) * 2003-12-22 2007-06-14 ブラッコ・リサーチ・ソシエテ・アノニム 造影イメージング用の活性成分を有する気体封入マイクロベシクルのアセンブリー
US20050260137A1 (en) * 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US7229690B2 (en) 2004-07-26 2007-06-12 Massachusetts Institute Of Technology Microspheres including nanoparticles
US9248204B2 (en) 2004-08-18 2016-02-02 Bracco Suisse S.A. Gas-filled microvesicles composition for contrast imaging
US20080019918A1 (en) * 2004-09-10 2008-01-24 Takao Aoki Medicinal Preparation
US20070264199A1 (en) * 2005-09-26 2007-11-15 Labhasetwar Vinod D Magnetic nanoparticle composition and methods for using the same
US8361494B2 (en) * 2006-03-10 2013-01-29 The Trustees Of The University Of Pennsylvania Biomimetic iron-oxide-containing lipoprotein and related materials
AU2007293888B2 (en) 2006-09-05 2013-05-02 Bracco Suisse S.A. Gas-filled microvesicles with polymer-modified lipids
JP5607368B2 (ja) 2006-12-18 2014-10-15 コロロッビア イタリア ソシエタ ペル アチオニ 温熱療法において適用される磁性ナノ粒子、その調製、および、薬理学的用途を有する構造体における使用
US8784659B2 (en) * 2007-08-08 2014-07-22 General Electric Company Method for controlling microbial biofilm in aqueous systems
WO2009145813A1 (en) * 2008-03-04 2009-12-03 Qd Vision, Inc. Particles including nanoparticles, uses thereof, and methods
FR2934955B1 (fr) 2008-08-14 2011-07-08 Commissariat Energie Atomique Encapsulation d'agents therapeutiques lipophiles ou amphiphiles dans des nanoemulsions
FR2934953B1 (fr) 2008-08-14 2011-01-21 Commissariat Energie Atomique Nanoemulsions de nanocristaux
FR2934954B1 (fr) 2008-08-14 2011-07-22 Commissariat Energie Atomique Emulsion fluorescente de vert d'indocyanine
AU2009301141B2 (en) * 2008-10-07 2015-08-27 Bracco Suisse S.A. Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
CN102482457B (zh) 2009-09-09 2015-04-15 Qd视光有限公司 包含纳米颗粒的颗粒、其应用和方法
WO2011031876A1 (en) 2009-09-09 2011-03-17 Qd Vision, Inc. Formulations including nanoparticles
JP5678565B2 (ja) * 2009-12-08 2015-03-04 Jnc株式会社 磁性微粒子およびその製造方法
US20110217379A1 (en) * 2010-03-08 2011-09-08 Davis Llp Magnetic nanomaterials and methods for chemoembolisation
KR101174470B1 (ko) 2010-04-08 2012-08-16 한국세라믹기술원 자성 실리카 리포좀 나노입자 및 이의 제조방법
TWI428284B (zh) 2010-11-05 2014-03-01 Nat Univ Chung Cheng Sea urchin iron oxide and its manufacturing method
US8895068B2 (en) 2010-12-15 2014-11-25 General Electric Company Nanoparticle composition and associated methods thereof
US8889103B2 (en) 2010-12-15 2014-11-18 General Electric Company Diagnostic agent composition and associated methods thereof
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
JP6313329B2 (ja) 2012-12-21 2018-04-18 ブラッコ・スイス・ソシエテ・アノニムＢｒａｃｃｏ Ｓｕｉｓｓｅ ＳＡ ガス封入マイクロベシクル
WO2016191549A1 (en) * 2015-05-26 2016-12-01 Intezyne Technologies Iron stabilized micelles as magnetic contrast agents
FR3103376B1 (fr) * 2019-11-26 2021-11-12 Univ Bordeaux Ferrofluide huileux biocompatible et procédé de préparation

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4331645A (en) * 1981-04-20 1982-05-25 Reynolds Metals Company Alumina from alkali metal-aluminum chloride complexes
NL194579C (nl) * 1983-01-21 2002-08-05 Schering Ag Diagnostisch middel.
JPS6072830A (ja) * 1983-09-29 1985-04-24 Kao Corp ベシクル用組成物
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
DE3515373A1 (de) * 1985-04-27 1986-11-06 Merck Patent Gmbh, 6100 Darmstadt Stickstoffhaltige heterocyclen
US4675173A (en) * 1985-05-08 1987-06-23 Molecular Biosystems, Inc. Method of magnetic resonance imaging of the liver and spleen
JPS6295134A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
DE3619746A1 (de) * 1986-06-12 1987-12-17 Basf Ag Superparamagnetische feststoffteilchen
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US4951675A (en) * 1986-07-03 1990-08-28 Advanced Magnetics, Incorporated Biodegradable superparamagnetic metal oxides as contrast agents for MR imaging
DK175531B1 (da) * 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
US5124289A (en) * 1986-12-29 1992-06-23 Aluminum Company Of America Surface treated permeable inorganic membranes and process of making same
US4994429A (en) * 1986-12-29 1991-02-19 Aluminum Company Of America Active material useful as adsorbent comprising metal oxide/hydroxide particles reacted with phosphorus-containing organic acid group of organic compound having unreacted acid group
US4929589A (en) * 1986-12-29 1990-05-29 Aluminum Company Of America Metal oxide/hydroxide particles coated with phosphate esters
US4983566A (en) * 1987-03-09 1991-01-08 Aluminum Company Of America Surface-modified adsorbent comprising metal oxide/hydroxide particles reacted with one or more perfluorinated organic acids
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
US5230882A (en) * 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
US5246707A (en) * 1990-04-26 1993-09-21 Haynes Duncan H Sustained release delivery of water-soluble bio-molecules and drugs using phospholipid-coated microcrystals, microdroplets and high-concentration liposomes
US5091188A (en) * 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
CA2046997C (en) * 1990-07-16 2000-12-12 Hiroshi Kikuchi Liposomal products
DE4100470A1 (de) * 1991-01-09 1992-07-16 Byk Gulden Lomberg Chem Fab Echokontrastmittel
JP3272736B2 (ja) * 1991-01-31 2002-04-08 協和醗酵工業株式会社 リポソーム製剤
CA2064683A1 (en) * 1992-03-26 1993-09-27 Krishna Mohan Rao Kallury Formation of thermostable enzymes with extra-ordinary heat tolerance by immobilization on phospholipid matrices
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
US5494744A (en) * 1994-10-12 1996-02-27 Kimberly-Clark Corporation Method of applying a protein coating to a substrate and article thereof
US20120231528A1 (en) * 2009-11-10 2012-09-13 Microphyt Reaction casing for a photosynthetic reactor and associated photosynthetic reactor

Also Published As

Publication number Publication date
CN1089470A (zh) 1994-07-20
AU660108B2 (en) 1995-06-08
CA2119654A1 (en) 1994-03-03
DK0607401T3 (da) 1996-11-25
HUT75149A (en) 1997-04-28
US5464696A (en) 1995-11-07
IS1648B (is) 1997-03-25
US5545395A (en) 1996-08-13
ATE144714T1 (de) 1996-11-15
JP2968588B2 (ja) 1999-10-25
AU4705493A (en) 1994-03-15
IS4058A (is) 1994-02-14
MX9304924A (es) 1994-08-31
KR100307773B1 (ko) 2001-12-28
DE69305730D1 (de) 1996-12-05
FI941677A7 (fi) 1994-04-12
NO941311L (no) 1994-04-12
EP0607401B1 (en) 1996-10-30
DE69305730T2 (de) 1997-05-28
NO307244B1 (no) 2000-03-06
JPH07503976A (ja) 1995-04-27
FI941677L (fi) 1994-04-12
IL106493A0 (en) 1993-11-15
GR3022288T3 (en) 1997-04-30
US5587199A (en) 1996-12-24
NO941311D0 (no) 1994-04-12
EP0607401A1 (en) 1994-07-27
FI941677A0 (fi) 1994-04-12
HU9401038D0 (en) 1994-07-28
IL106493A (en) 1997-02-18
HU221805B1 (hu) 2003-01-28
CA2119654C (en) 2001-02-06
NZ254791A (en) 1996-11-26
WO1994004197A1 (en) 1994-03-03
CN1076205C (zh) 2001-12-19

Similar Documents

Publication Publication Date Title
ES2094558T3 (es) Particulas para formacion de imagenes de resonancia magnetica nuclear (nmr) y metodo de fabricacion.
ES2600791T3 (es) Procedimiento para estabilizar composiciones de peróxido de hidrógeno
Dalitz Isotopic Spin Changes in τ and θ Decay
ES502647A0 (es) Un procedimiento para la preparacion de una composicion de rapamicina inyectable
ES2062365T3 (es) Composicion de champu.
AR109981A1 (es) Formulación liposomal
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
MX9301885A (es) Esteres de alcoxilato grasos de acidos dicarboxilicos y tricarboxilicos alifaticos y aromaticos.
AR109757A1 (es) Nanopartículas lipídicas modificadas con apo-e para la administración de fármacos a tejidos específicos y métodos terapéuticos
ATE373466T1 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
YU91790A (sh) Postopek za pripravo substituiranih aminoalkilfosfinskih kislin
DE3888251D1 (de) Verfahren zur Herstellung von Metallsalzen von Phosphor- und Phosphonsäureestern.
ES2038156T3 (es) Procedimiento para la obtencion de acidos quinolincarboxilicos.
ES2175439T3 (es) Composiciones que contienen al menos un acido nucleico.
ATE156114T1 (de) Neutronenaktivierbare kationen enthaltende lipophile zusammensetzungen
ES2165971T3 (es) Suspensiones de liposomas como agentes de contraste para la imagineria de la sangre.
Waltham et al. Association of ferri-and ferro-cytochrome c with lipid multilayers: a 31P solid-state NMR study
IL34985A0 (en) Triazolothiazole esters of phosphoric,phosphonic and phosphinic acids and of the corresponding thiono acids,their preparation and their use as insecticides and acaricides
Zou et al. Targeted delivery of contrast agents to the tympanic medial wall at minimum amount and the efficient uptake in the inner ear through oval and round windows
Lange The myelinated parallel fibers of the cerebellar cortex and their regional distribution
IT1086399B (it) Esteri oppure esteriamidi pirazolil(tion) (tiol)-fosforici(fosfonici) alcossimetil-sostituiti oppure alchil-tiometilsostituiti,procedimento per la loro preparazione e loro impiego come insetticidi e come acaricidi
Baral et al. Rajiv Gandhi's China Diplomacy: Dynamics and Problems
Burford et al. Metabolism of Phosphatido-Peptide and Phospholipid in the Supersensitive Submaxillary Gland of the Cat, in vivo
FR2356659A1 (fr) Agents ignifugeants du type phosphonate pour polymeres
JPS5363398A (en) Thiazinotriazole phosphoric acid esters, their preparation, and insecticidesand acarisides

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 607401

Country of ref document: ES